---
title: "Lanifibranor (IVA337) in Metabolic dysfunction-associated steatohepatitis with F2 to F3 fibrosis: Pharmacokinetics"
description: "Formulary evidence on Lanifibranor (IVA337) in Metabolic dysfunction-associated steatohepatitis with F2 to F3 fibrosis: Pharmacokinetics. Topics: Clinical pharmacology studies described in the NATIVE protocol; Absorption: solubility class and food effect; Time to maximum concentration, half-life, dose proportionality, and steady state in humans; Less than dose-proportional exposure at 400, 800, and 1400 mg: participants with type 2 diabetes; 8 further topics. 12 evidence topics quoted from 8 sources."
canonical: "https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis/product-information-and-disease-description/pharmacokinetics"
published: "2026-11-18T22:34:49-05:00"
modified: "2026-11-18T22:34:49-05:00"
---

# Lanifibranor (IVA337) in Metabolic dysfunction-associated steatohepatitis with F2 to F3 fibrosis: Pharmacokinetics

<a id="heading-2.1.2.6.3"></a>

## 2.1.2.6.3 Pharmacokinetics

<a id="topic-2.1.2.6.3-1"></a>

### Clinical pharmacology studies described in the NATIVE protocol

> “Three clinical studies have been conducted in healthy subjects, one study in patients with type 2 diabetes, and one phase II study is ongoing in the treatment of diffuse cutaneous systemic sclerosis.”
> “The objectives of study S337.1.001 were to assess pharmacokinetics, pharmacodynamics, safety and tolerability of lanifibranor after single increasing doses and after multiple increasing doses.”
> “The objectives of study S337.1.005 were to assess the relative bioavailability of lanifibranor oral suspension and capsules (cross-over design), and to assess, in vivo in human, the completeness of excretion, routes and rates of elimination of radioactivity, the metabolic pathways, and identity of lanifibranor metabolites after single administration of 14C-IVA337.”
> “Treatments included single doses of 25 mg to 1000 mg, multiple doses of 150 mg to 1500 mg once daily for 14 consecutive days, and once daily doses of 400, 800, and 1400 mg for 4 weeks.”

Source: [Inventiva NATIVE protocol (2019)](https://cdn.clinicaltrials.gov/large-docs/70/NCT03008070/Prot_002.pdf)

<a id="topic-2.1.2.6.3-2"></a>

### Absorption: solubility class and food effect

> “Lanifibranor is considered as a class II compound as regard to the Biopharmaceutics Classification System (BCS) Guidance: high permeability and low solubility.”
> “It was evidenced in all tested species that lanifibranor absorption is dependent on the drug substance form and formulation, leading to a bioavailability in animals from 15% up to >80%.”
> “An enterohepatic recycling was evidenced, and a food effect was observed in human in the presence of high fat breakfast.”

Source: [Inventiva NATIVE protocol (2019)](https://cdn.clinicaltrials.gov/large-docs/70/NCT03008070/Prot_002.pdf)

<a id="topic-2.1.2.6.3-3"></a>

### Time to maximum concentration, half-life, dose proportionality, and steady state in humans

> “After oral administration in human, maximum plasma levels (Cmax) of lanifibranor were reached at about 1.0-3.5 h, and terminal plasma elimination half-life was around 10-15 h.”
> “Both Area Under the Curve (AUC) and Cmax increased in a linear but slightly less than dose-proportional manner.”
> “Steady-state lanifibranor concentrations were generally achieved by Day 3 after daily dose administration, with no significant accumulation.”

Source: [Inventiva NATIVE protocol (2019)](https://cdn.clinicaltrials.gov/large-docs/70/NCT03008070/Prot_002.pdf)

<a id="topic-2.1.2.6.3-4"></a>

### Less than dose-proportional exposure at 400, 800, and 1400 mg: participants with type 2 diabetes

> “The phase 2a, multicenter, randomized, double-blind, placebo-controlled, parallel-group, 28-day study evaluated lanifibranor in participants with T2DM who were on metformin monotherapy (Figure 1)”
> “Exposure to lanifibranor increased in a less than dose-proportional manner following oral dosing with 400, 800, and 1400 mg once daily”

Source: [Francque et al. (2026)](https://inventivapharma.com/wp-content/uploads/MASH-2026-Clinical-PK-PD-poster_LUM-03426_v2.pdf)

<a id="topic-2.1.2.6.3-5"></a>

### Distribution and plasma protein binding

> “The mean apparent volume of distribution Vz/F ranged from 318 to 607 L in healthy subjects.”
> “IVA337 binds very highly to plasma proteins in all tested species (~99.9%) and no affinity to blood cells was observed.”
> “By autoradiography in rat, lanifibranor was shown to be mainly distributed in the excretory organs (liver, kidneys, lungs, gastrointestinal tract) and in placenta in pregnant rats with no affinity for the melanin tissues and with very limited central nervous system penetration.”

Source: [Inventiva NATIVE protocol (2019)](https://cdn.clinicaltrials.gov/large-docs/70/NCT03008070/Prot_002.pdf)

<a id="topic-2.1.2.6.3-6"></a>

### Metabolism: circulating parent drug and main human metabolites

> “AUC indicated approximately 23% of the radioactivity in plasma were related to lanifibranor, while 77% were related to its metabolites.”
> “Among metabolites identified in plasma, faeces and urine, the main lanifibranor metabolites observed in human were the acyl glucuronide (IV1197736, with similar exposure to that of the parent compound), a monohydroxylated (IV1537661) and the benzothiazole ring opened lanifibranor derivative (IV1197347).”
> “The three major human metabolites, IV1197736, IV1197347 and IV1537661, were also found devoid of genotoxic potential in a bacterial reverse mutation test and a mammalian cell assay.”

Source: [Inventiva NATIVE protocol (2019)](https://cdn.clinicaltrials.gov/large-docs/70/NCT03008070/Prot_002.pdf)

<a id="topic-2.1.2.6.3-7"></a>

### Elimination: faecal excretion in the radiolabeled study

> “Lanifibranor-related radioactivity elimination was mainly faecal (>85%) and the urinary excretion was minor (<7%) with a very low renal clearance.”
> “The excretion was essentially complete after 3 days.”

Source: [Inventiva NATIVE protocol (2019)](https://cdn.clinicaltrials.gov/large-docs/70/NCT03008070/Prot_002.pdf)

<a id="topic-2.1.2.6.3-8"></a>

### Supratherapeutic multiple ascending dose study in healthy men

> “The study will be a double-blind, randomized, placebo-controlled, multiple ascending dose study with lanifibranor.”
> “A Double-blind, Placebo-controlled, Safety, Tolerability and Pharmacokinetic Study in Healthy Male Volunteers in Order to Define Lanifibranor (IVA337) Supra-therapeutic Dose in a Multiple Dosing Regimen”
> “The study will consist of up to 3 cohorts of 12 subjects each; therefore, approximately 36 subjects will be included in this study.”
> “All subject will receive first a single dose of 400 mg moxifloxacin, under open-label fasting conditions at Day -8 (assay sensitivity).”
> “Single daily oral dose during 14 days”

Source: [ClinicalTrials.gov NCT03866369](https://clinicaltrials.gov/study/NCT03866369)

<a id="topic-2.1.2.6.3-9"></a>

### QT/QTc study in 217 healthy participants at 1200 and 2400 mg/day

> “In December 2021, we announced positive results of a clinical QT/QTc study demonstrating lanifibranor had no impact on QT/QTc intervals.”
> “The QT/QTc study was conducted in 217 healthy subjects who were randomized into 4 arms: placebo, lanifibranor 1200mg/day, lanifibranor 2400 mg/day and moxifloxacin 400mg/ day (positive control).”
> “The primary endpoint was electrocardiogram (ECG) and monitored during the first 24 hours.”
> “Results showed that repeated daily administration of lanifibranor dosed at 2-fold higher than anticipated maximal therapeutic dose had no effect on cardiac electrical activity as shown by achieving the pre-specified primary endpoint of demonstrating no prolongation of the QT interval in healthy subjects.”

Source: [Inventiva Form 20-F (2026)](https://www.sec.gov/Archives/edgar/data/1756594/000110465926040704/iva-20251231x20f.htm)

<a id="topic-2.1.2.6.3-10"></a>

### Pharmacokinetic study in healthy Chinese adults at 800 and 1200 mg

> “The primary objective of this study is to evaluate the pharmacokinetic profile of lanifibranor after single dose and multiple doses 800 and 1200 mg in healthy adult Chinese subjects.”
> “Approximately 24 healthy Chinese volunteers, male and female will be recruited and divided into two equal groups (12 subjects per dose).”
> “In Part B, lanifibranor 800 mg is given once daily for 7 consecutive days (followed by 7 days follow-up).”

Source: [ClinicalTrials.gov NCT06126562](https://clinicaltrials.gov/study/NCT06126562)

> “In addition, CTTQ will also conduct in parallel a Phase I clinical pharmacology study to evaluate the pharmacokinetics of the 800mg/day and 1200mg/day doses of lanifibranor in healthy Chinese subjects.”

Source: [Inventiva CTTQ China IND release (2023)](https://inventivapharma.com/wp-content/uploads/inventiva-documents/Inventiva-PR-IND-Lanifibranor-China-EN-05-25-2023.pdf)

<a id="topic-2.1.2.6.3-11"></a>

### Phase 1 study in Japan: 32 participants dosed once daily for 14 days

> “As part of the single-center study, 32 subjects will be separated randomly into four cohorts and will receive lanifibranor once daily for 14 days.”

Source: [Inventiva Hepalys phase 1 initiation release (2025)](https://inventivapharma.com/wp-content/uploads/inventiva-documents/Inventiva-PR-Phase-1-Hepalys-Pharma-EN-02-20-2025.pdf)

<a id="topic-2.1.2.6.3-12"></a>

### Bioequivalence study in healthy volunteers

> “A Randomised, Open-Label, Single-Centre, Study to Evaluate the Bioequivalence of Lanifibranor”
> “Human Pharmacology (Phase I)- Bioequivalence Study”

Source: [EU Clinical Trials Information System 2025-524385-18-00](https://euclinicaltrials.eu/ctis-public/view/2025-524385-18-00)

## Related pages
- [Lanifibranor (IVA337): Metabolic dysfunction-associated steatohepatitis with F2 to F3 fibrosis](https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis) · [Markdown](https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis.md)
- [Lanifibranor (IVA337) in Metabolic dysfunction-associated steatohepatitis with F2 to F3 fibrosis: Terms and abbreviations](https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis/terms-and-abbreviations.md)
- [Lanifibranor (IVA337): Metabolic dysfunction-associated steatohepatitis with F2 to F3 fibrosis](https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis/executive-summary) · [Markdown](https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis/executive-summary.md)
- [Lanifibranor (IVA337) in Metabolic dysfunction-associated steatohepatitis with F2 to F3 fibrosis: Product information and disease description](https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis/product-information-and-disease-description.md)
- [Lanifibranor (IVA337) in Metabolic dysfunction-associated steatohepatitis with F2 to F3 fibrosis: Clinical evidence](https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis/clinical-evidence.md)
- [Lanifibranor (IVA337) in Metabolic dysfunction-associated steatohepatitis with F2 to F3 fibrosis: Economic information and modeling report](https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis/economics) · [Markdown](https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis/economics.md)
- [Lanifibranor (IVA337) in Metabolic dysfunction-associated steatohepatitis with F2 to F3 fibrosis: References](https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis/references) · [Markdown](https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis/references.md)
